avdoralimab   Click here for help

GtoPdb Ligand ID: 11345

Synonyms: anti-hC5aR-32F3A6 GL | IPH-5401 | NN-8210 | NNC-0215-0384
Immunopharmacology Ligand
Compound class: Antibody
Comment: Avdoralimab (IPH5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1, and blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. It has immunomodulating activity.
No information available.
Summary of Clinical Use Click here for help
Avdoralimab (IPH5401) has advanced to clinical evaluation as an addition to cancer immunotherapy and for autoimmune diseases.
SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, avdoralimab was entered into clinical trial, with the purpose of determining potential efficacy of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in COVID-19 patients [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04371367 Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) Phase 2 Interventional Assistance Publique Hopitaux De Marseille
NCT04563923 Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Phase 2 Interventional Centre Hospitalier Universitaire de Nice
NCT03665129 IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1 Interventional Innate Pharma In combination with the anti-PD-L1 immune checkpoint anti-cancer agent .
NCT01611688 First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis Phase 1 Interventional Novo Nordisk A/S
NCT01955603 A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis Phase 1 Interventional Novo Nordisk A/S